• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多区域 H-MRS 检测和应用神经化学谱在帕金森病中的研究。

Detection and application of neurochemical profile by multiple regional H-MRS in Parkinson's disease.

机构信息

Department of Neurologythe Second Affiliated Hospital of Shantou University Medical College Shantou Guangdong China.

Department of Preventive Medicine Shantou University Medical College Shantou Guangdong China.

出版信息

Brain Behav. 2017 Aug 13;7(9):e00792. doi: 10.1002/brb3.792. eCollection 2017 Sep.

DOI:10.1002/brb3.792
PMID:28948086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5607555/
Abstract

INTRODUCTION

The accurate diagnosis and monitoring of idiopathic Parkinson disease (PD), a progressive neurodegenerative disorder, has not been fully developed. This study sought to identify a neurochemical profile in multiple regions of the PD brain and healthy controls by proton magnetic resonance spectroscopy (H-MRS). We aimed to track changes of the brain neurochemical, quantify neuronal loss, and further determine the diagnostic value of H-MRS.

METHODS

PD patients and healthy controls recruited from Second Affiliated Hospital of Shantou University Medical College, Shantou, southern China, underwent H-MRS. Chemical information was obtained for ratios of N-acetylaspartate to creatine (NAA/Cr), NAA to choline (NAA/Cho), and Cho to Cr for substantia nigra, globus pallidus, prefrontal lobe, hippocampus, cuneus gyrus, and dorsal thalamus regions.

RESULTS

Compared to the 20 healthy controls (12 male, age 58.75 ± 5.03 years), the 42 patients (21 male, age 61.60 ± 6.40 years) showed lower NAA/Cr and NAA/Cho ratios in substantia nigra, globus pallidus, prefrontal lobe, hippocampus, cuneus gyrus and dorsal thalamus regions (<.01); NAA/Cr and NAA/Cho ratios were reduced for both patients with unilateral and mild/no cognitive impairment (<.01); Unified Parkinson's Disease Rating Scale score was inversely correlated with NAA/Cr ratios in the substantia nigra ( = -.32; =.042).

CONCLUSION

NAA/Cr and NAA/Cho ratios may be useful metabolic biomarkers for early diagnosis of PD. Multi-voxel H-MRS can provide information on brain neurochemistry and may be a promising technique for diagnosis of and monitoring neuronal loss in PD.

摘要

简介

特发性帕金森病(PD)是一种进行性神经退行性疾病,其准确诊断和监测尚未完全实现。本研究旨在通过质子磁共振波谱(H-MRS)确定 PD 大脑和健康对照组的多个区域的神经化学特征。我们旨在跟踪大脑神经化学物质的变化,量化神经元丢失,并进一步确定 H-MRS 的诊断价值。

方法

来自中国南方汕头大学医学院第二附属医院的 PD 患者和健康对照者接受了 H-MRS。对黑质、苍白球、前额叶、海马、楔前叶和背侧丘脑区域的 N-乙酰天冬氨酸与肌酸(NAA/Cr)、N-乙酰天冬氨酸与胆碱(NAA/Cho)和 Cho 与 Cr 的比值进行化学信息采集。

结果

与 20 名健康对照者(12 名男性,年龄 58.75±5.03 岁)相比,42 名患者(21 名男性,年龄 61.60±6.40 岁)的黑质、苍白球、前额叶、海马、楔前叶和背侧丘脑区域的 NAA/Cr 和 NAA/Cho 比值均较低(<.01);单侧和轻度/无认知障碍的患者的 NAA/Cr 和 NAA/Cho 比值均降低(<.01);统一帕金森病评定量表评分与黑质 NAA/Cr 比值呈负相关(=-.32;=.042)。

结论

NAA/Cr 和 NAA/Cho 比值可能是 PD 早期诊断的有用代谢生物标志物。多体素 H-MRS 可提供有关大脑神经化学的信息,可能是 PD 神经元丢失诊断和监测的有前途的技术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/d22fc9f37ab7/BRB3-7-e00792-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/b6c215820559/BRB3-7-e00792-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/192e35e80208/BRB3-7-e00792-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/d22fc9f37ab7/BRB3-7-e00792-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/b6c215820559/BRB3-7-e00792-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/192e35e80208/BRB3-7-e00792-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb25/5607555/d22fc9f37ab7/BRB3-7-e00792-g003.jpg

相似文献

1
Detection and application of neurochemical profile by multiple regional H-MRS in Parkinson's disease.通过多区域 H-MRS 检测和应用神经化学谱在帕金森病中的研究。
Brain Behav. 2017 Aug 13;7(9):e00792. doi: 10.1002/brb3.792. eCollection 2017 Sep.
2
Region-specific Cerebral Metabolic Alterations in Parkinson's Disease Patients With/without Mild Cognitive Impairment.帕金森病患者伴或不伴轻度认知障碍的区域性脑代谢改变。
Neuroscience. 2024 Jul 23;551:254-261. doi: 10.1016/j.neuroscience.2024.05.039. Epub 2024 Jun 6.
3
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.在临床环境中,后扣带回皮质中的代谢物比率与帕金森病的认知衰退无关。
Parkinsonism Relat Disord. 2016 Jan;22:54-61. doi: 10.1016/j.parkreldis.2015.11.008. Epub 2015 Nov 12.
4
Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: a proton magnetic resonance spectroscopy study.重度抑郁症与双相抑郁症生化异常的相似性:一项质子磁共振波谱研究
J Affect Disord. 2014 Oct;168:380-6. doi: 10.1016/j.jad.2014.07.024. Epub 2014 Jul 24.
5
Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.帕金森病轻度认知障碍患者中明显的 N-乙酰天门冬氨酸和胆碱代谢物变化。
Parkinsonism Relat Disord. 2013 Mar;19(3):329-34. doi: 10.1016/j.parkreldis.2012.11.012. Epub 2012 Dec 11.
6
Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.质子磁共振波谱在帕金森病黑质代谢物中的应用。
Brain Imaging Behav. 2014 Mar;8(1):97-101. doi: 10.1007/s11682-013-9251-2.
7
Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.丘脑切开术后帕金森病的质子磁共振波谱变化
Eur J Radiol. 2003 Sep;47(3):179-87. doi: 10.1016/s0720-048x(02)00211-5.
8
Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.多巴胺能治疗后新发帕金森病的代谢变化:一项质子磁共振波谱研究。
Neurosci Lett. 2015 Jul 10;599:55-60. doi: 10.1016/j.neulet.2015.05.044. Epub 2015 May 22.
9
Evaluation of the Braak staging of brain pathology with H-MRS in patients with Parkinson's disease.帕金森病患者脑病理Braak分期的氢质子磁共振波谱评估
Neurosci Lett. 2017 Nov 1;660:57-62. doi: 10.1016/j.neulet.2017.08.050. Epub 2017 Aug 24.
10
Whole-brain proton MR spectroscopic imaging in Parkinson's disease.帕金森病的全脑质子磁共振波谱成像
J Neuroimaging. 2014 Jan-Feb;24(1):39-44. doi: 10.1111/j.1552-6569.2012.00733.x. Epub 2012 Dec 10.

引用本文的文献

1
Applications of magnetic resonance spectroscopy in diagnosis of neurodegenerative diseases: A systematic review.磁共振波谱在神经退行性疾病诊断中的应用:一项系统综述。
Heliyon. 2024 Apr 30;10(9):e30521. doi: 10.1016/j.heliyon.2024.e30521. eCollection 2024 May 15.
2
Comparative study of bilateral putamen for patients with severe Parkinson's disease detected by H magnetic resonance spectroscopy.采用氢磁共振波谱对重度帕金森病患者双侧壳核的对比研究。
Quant Imaging Med Surg. 2023 Oct 1;13(10):6646-6655. doi: 10.21037/qims-23-231. Epub 2023 Aug 22.
3
A comparative study of posterior cingulate metabolism in patients with mild cognitive impairment due to Parkinson's disease or Alzheimer's disease.

本文引用的文献

1
Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.质子磁共振波谱在帕金森病黑质和苍白球病理变化监测中的应用。
AJR Am J Roentgenol. 2016 Feb;206(2):385-9. doi: 10.2214/AJR.14.14052.
2
Neuroimaging of Parkinson's disease: Expanding views.帕金森病的神经影像学:不断拓展的视野。
Neurosci Biobehav Rev. 2015 Dec;59:16-52. doi: 10.1016/j.neubiorev.2015.09.007. Epub 2015 Sep 26.
3
Proton MR Spectroscopy for Diagnosis and Evaluation of Treatment Efficacy in Parkinson Disease.
帕金森病或阿尔茨海默病所致轻度认知障碍患者后扣带回代谢的对比研究。
Sci Rep. 2023 Aug 30;13(1):14241. doi: 10.1038/s41598-023-41569-5.
4
How should we be using biomarkers in trials of disease modification in Parkinson's disease?我们应该如何在帕金森病疾病修饰治疗的临床试验中使用生物标志物?
Brain. 2023 Dec 1;146(12):4845-4869. doi: 10.1093/brain/awad265.
5
Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning.使用磁共振波谱成像和机器学习技术鉴定帕金森病患者轻度认知障碍的代谢相关性。
MAGMA. 2022 Dec;35(6):997-1008. doi: 10.1007/s10334-022-01030-6. Epub 2022 Jul 22.
6
Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study.单胺氧化酶B抑制剂对帕金森病患者神经代谢特征的影响:一项质子磁共振波谱研究
J Clin Med. 2022 Mar 30;11(7):1931. doi: 10.3390/jcm11071931.
7
Proton Magnetic Resonance Spectroscopy for Diagnosis of Non-Motor Symptoms in Parkinson's Disease.质子磁共振波谱用于帕金森病非运动症状的诊断
Front Neurol. 2022 Feb 28;13:594711. doi: 10.3389/fneur.2022.594711. eCollection 2022.
8
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.帕金森病和非典型帕金森综合征的神经影像学进展
Front Neurol. 2020 Oct 15;11:572976. doi: 10.3389/fneur.2020.572976. eCollection 2020.
9
Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging.早期帕金森病的神经代谢特征改变:一项采用短回波时间全脑磁共振波谱成像的研究。
Front Neurol. 2019 Jul 17;10:777. doi: 10.3389/fneur.2019.00777. eCollection 2019.
质子磁共振波谱在帕金森病诊断和疗效评估中的应用。
Radiology. 2016 Feb;278(2):505-13. doi: 10.1148/radiol.2015142764. Epub 2015 Aug 4.
4
The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes.小脑质子磁共振波谱在帕金森综合征鉴别诊断中的作用。
Parkinsonism Relat Disord. 2015 Aug;21(8):929-37. doi: 10.1016/j.parkreldis.2015.05.025. Epub 2015 Jun 3.
5
Biomarkers in Parkinson's disease (recent update).帕金森病的生物标志物(最新进展)。
Neurochem Int. 2013 Sep;63(3):201-29. doi: 10.1016/j.neuint.2013.06.005. Epub 2013 Jun 19.
6
Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.帕金森病轻度认知障碍患者中明显的 N-乙酰天门冬氨酸和胆碱代谢物变化。
Parkinsonism Relat Disord. 2013 Mar;19(3):329-34. doi: 10.1016/j.parkreldis.2012.11.012. Epub 2012 Dec 11.
7
Whole-brain proton MR spectroscopic imaging in Parkinson's disease.帕金森病的全脑质子磁共振波谱成像
J Neuroimaging. 2014 Jan-Feb;24(1):39-44. doi: 10.1111/j.1552-6569.2012.00733.x. Epub 2012 Dec 10.
8
The MoCA: well-suited screen for cognitive impairment in Parkinson disease.MoCA:适合帕金森病认知障碍的筛查工具。
Neurology. 2010 Nov 9;75(19):1717-25. doi: 10.1212/WNL.0b013e3181fc29c9.
9
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.运动障碍协会赞助的统一帕金森病评定量表修订版(MDS-UPDRS):量表介绍及临床测量测试结果
Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.
10
The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease.蒙特利尔认知评估作为帕金森病认知障碍的筛查工具。
Mov Disord. 2008 May 15;23(7):1043-1046. doi: 10.1002/mds.22017.